相关实验视频

Updated: Jan 16, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

EGCG重塑了TGF-β宫癌微环境,使其具有免疫反应能力

Jayapradha Gnanagurusamy¹, Rajalakshmi Sabanayagam¹, Sneha Krishnamoorthy¹

¹Department of Biochemistry, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India; Centre for Cancer Research, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India.

Cellular immunology

|September 26, 2025

概括

在宫癌 (CC) 免疫疗法中,epigallocatechin gallate (EGCG) 通过向TGF-β和调节PD-L1和膜辅因子蛋白 (mCRPs) 来显示出有前途的潜力. 这项研究揭示了EGCG的EGCG.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

通过了解免疫调节剂和TGF-β,可以改善宫癌 (CC) 的治疗.
调查PD-L1,CD55和CD46在CC中的作用对于向治疗至关重要.

研究的目的:

分析宫癌中PD-L1,CD55,CD46的表达,生存相关性和免疫透.
评估TGF-β和EGCG对CC细胞的影响及其与外周血液单核细胞 (PBMC) 的相互作用.

主要方法:

使用OncoDB,TIMER 2.0和TCIA进行表达和生存分析.
进行了RT-PCR,西部涂抹和细胞共同培养试验.
在CC细胞和球状体中评估活力,亡,ROS和MMP-2.

主要成果:

在HPV16阳性CC中观察到升级的PD-L1和CD55,而CD46没有显著的变化.
增加的PD-L1,CD55和CD46与减少的整体存活时间 (OS) 相相关.
在CC模型中,EGCG治疗降低了PD-L1,CD55和CD46的表达,抑制了增殖,并诱导了亡.

结论:

EGCG显示出作为宫癌的免疫治疗剂的潜力.
向TGF-β和调节PD-L1和膜辅因子蛋白 (mCRPs) 是EGCG作用的关键机制.
对于CC的治疗策略,EGCG需要进一步调查.

关键词:

宫癌共同培养宫癌共同培养对于 EGCG 的情况来说,这是一项非常重要的决定.在PD-L1中.球形球体是指球形球体.在TGF-β的基础上.最多的CRP可以使用.

更多相关视频

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Spheroid Assay to Measure TGF-β-induced Invasion

Spheroid Assay to Measure TGF-β-induced Invasion

Published on: November 16, 2011

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...

The Tumor Microenvironment

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...